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ABSTRACT
The use of a quantifiable and reproducible measurement tool for skin manifestations of chronic graft-versus-
host disease (cGVHD) is key for the successful assessment and documentation of therapeutic response. Skin
scoring methods for use in clinical trials have not been validated for application in patients suffering from
cGVHD. For this purpose we performed a prospective single-center pilot study to validate a skin-scoring tool
developed at our institution for evaluating cutaneous involvement of cGVHD approximately 10 years ago. It
combines percentage of involved body surface area (BSA) divided into 10 separate anatomic regions with
manifestations of cGVHD coded from 0 (normal skin) to 4 (hidebound skin, unmovable sclerosis). Sixteen
patients were examined separately by 4 trained physicians 3 times on 2 consecutive days for a total of 192
individual skin assessments; intraobserver and interobserver reliability were calculated. Good to excellent
intraclass correlation coefficients (ICC) were obtained in almost all scores including erythematous lesions in
areas with scores 3 and 4 for all observers. Moderate to good interrater reliability for observers 1 to 4 was seen
in lesions with scores 0, 3, and 4, respectively. A marked improvement of interrater reliability in all scores and
examinations was observed when ICCs were calculated only for the more experienced observers 1 to 3. This
New Chronic GVHD Skin score is a reproducible, accurate, feasible, and inexpensive tool for use in selected
clinical trials of chronic cutaneous GVHD. Further studies with larger patient numbers and validation of this
new tool for assessment of treatment response are warranted.
© 2007 American Society for Blood and Marrow Transplantation
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cNTRODUCTION
Chronic graft-versus-host disease (cGVHD) is a
ajor complication of allogeneic hematopoietic stem
ell transplantation (HSCT) and has a signiﬁcant ef-
ect on quality of life and late mortality [1,2]. Re-
orted incidence rates of cGVHD after allogeneic
SCT range from 6% to 80% according to recipient
ge, donor type, hematopoietic stem cell source, graft
anipulation, and use of donor lymphocyte infusions
DLIs) [3-5].
Chronic GVHD is a multiorgan autoimmune-like
yndrome characterized by polymorphic clinical man-
festations with varying severity and clinical course. Dhe pathogenesis of cGVHD is still poorly under-
tood [6]. cGVHD can lead to debilitating conse-
uences, for example, joint contractures, loss of sight,
nd-stage lung disease, or mortality resulting from
rofound immune suppression leading to recurrent or
ife-threatening infections. Based on a recent pro-
osal and recommendation by the National Insti-
utes of Health (NIH) consensus development
roject the historical classiﬁcation of “limited” or
extensive” [7] has been replaced by a more speciﬁc
coring system [8].
Skin is the most frequently affected organ in
GVHD, and manifestations are highly variable.
iagnostic manifestations of skin involvement of
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H. T. Greinix et al.716GVHD include poikiloderma, lichen planus-like
ruption, deep sclerotic features, morphea-like super-
cial sclerotic features, or lichen sclerosus-like lesions.
evere sclerotic features characterized by thickened
ight and fragile skin are often associated with poor
ound-healing, inadequate lymphatic drainage, and
kin ulcers from minor trauma. Extensive skin in-
olvement (50% of body surface area) is a highly
igniﬁcant determinant of poor prognosis and is di-
ectly correlated with nonrelapse mortality (NRM) in
atients with cGVHD [9].
Clinical routine skin assessments are structured
o reﬂect anatomic levels of skin involvement in-
luding erythematous rash, movable sclerosis, hide-
ound skin, and ulceration. Abnormalities are as-
essed according to the percent of body surface area
BSA) involved as estimated by the rule of nines for
dults. Sclerotic skin manifestations may be as vari-
ble as the superﬁcial form of the disease and are
ifﬁcult to measure reliably. Typically they respond
lowly to therapy, and progression or regression of
clerotic lesions ideally should be assessed not only
ccording to the total surface area involved but also
ccording to the degree of involvement at any given
ite.
To date, no validated scale exists for assessing
clerotic skin changes of cGVHD. Measures such as
he Rodnan score [10] for assessment of systemic
clerosis might be helpful for clinical evaluation of
GVHD, but this scale does not adequatly measure
ichen sclerosus-like changes, subcutaneous in-
olvement without overlying skin thickening, and
s, in principle, associated with a potentially high
egree of subjective interpretation. For this reason,
he Rodnan score is not suitable for use in clinical
GVHD trials. Because reproducible and precise
ssessment of skin is essential for management and
iagnosis of cGVHD, indication for start or pro-
ongation of immunosuppressive therapy, and as-
essment of treatment response, we developed a
kin-speciﬁc score approximately 10 years ago based
n a modiﬁed scleroderma skin scoring method
riginally proposed for systemic sclerosis by Ka-
aleh and colleagues [11] for use by trained asses-
ors in clinical trials. Our score quantiﬁes the de-
ree of skin involvement by numerical units of 0 to
in 10 different body areas. Even though this New
hronic GVHD Skin Score has, up to the present,
ot been validated, it was successfully used for doc-
mentation of cGVHD in a recently ﬁnalized ran-
omized trial [12]. Therefore, in January 2006, we
onducted a 2-day session study to determine the
eproducibility (intraobserver reliability) and preci-
ion (interobserver reliability) of this new Skin
core for chronic GVHD at our institution.ATIENTS AND METHODS
atients
We enrolled 16 patients in this study: 12 patients
ith cutaneous cGVHD according to published cri-
eria [7,8], as shown in Table 1, and 4 with progressive
xtensive systemic sclerosis (SSc) of a median duration
f 40.5 (range, 10-120) months, respectively. The
able 1. Demographics and Chronic GVHD Characteristics
umber of patients 12
edian age in years (range) 44 (31-56)
ender
Male 7
Female 5
iagnosis at HSCT
AL 6
CML 2
NHL 3
CLL 1
onditioning regimen
Myeloablative 8
RIC 4
tem cell donors
Related 4
Unrelated 8
LA matching
HLA-identical 11
HLA-nonidentical 1
tem cell source
BM 2
PBSC 10
cute GVHD prophylaxis
Cyclosporine/MTX 8
Cyclosporine/MMF 4
rior acute GVHD 5 (42%)
Grades 0-I 2
Grades II-IV 3
nset type of chronic GVHD
De novo 7
Quiescent 2
Progressive 3
ime from chronic GVHD diagnosis to study
entry in months (range) 39 (24-109)
hronic GVHD organ involvement at study entry
Skin 12
Eye 6
Oral mucosa 4
Liver 2
Musculoskeletal 2
>2 organs 12
mmunosuppressive therapy at study entry
None 2
CSA alone 3
CSAMMF 1
ECP  CSA  Steroids 6
SCT indicates hematopoietic stem cell transplantation; AL, acute
leukemia; CML, chronic myelogenous leukemia; NHL, non-
Hodgkin=s lymphoma; CLL, chronic lymphatic leukemia; RIC,
reduced intensity conditioning; BM, bone marrow; PBSC, pe-
ripheral blood stem cells; CSA, cyclosporine A; MTX, metho-
trexate; MMF, mycophenolate mofetil; ECP, extracorporeal
photoimmunotherapy.
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Skin Score Validation—Chronic Graft-versus-Host Disease 717ater were included to increase the patient number
ecause additional patients with extensive cutaneous
GVHD were unable to participate during the 2-day
tudy period and the SSc lesions were comparable to
GVHD. Prior to study entry all patients signed an
nformed consent that was institutional review
oard approved. Fourteen patients (87.5%) had
ore than 5 regions of BSA affected by cGVHD or
Sc, including 11 (69%) with higher skin grading (3
nd 4) as deﬁned below. The remaining 2 patients
12.5%) had skin involvement limited to extremities
ith only 4 to 5 regions involved.
ew Skin Assessment Score for Chronic GVHD
For differentiation of normal skin from skin af-
ected by cGVHD for use in a prospective multicenter
andomized study we developed a skin-speciﬁc score
pproximately 10 years ago. Patients’ body surface
rea was divided into 10 regions (1  head, neck, and
calp; 2  chest; 3  abdomen and genitals; 4  back
nd buttocks; 5  right arm; 6  right hand; 7  left
rm; 8  left hand; 9  right leg and foot; and 10 
eft leg and foot) as shown in Figure 1. For every
egion coding from 0 to 4 (0  normal skin; 1 
iscolored, hypo- or hyperpigmentation, or alopecia;
 lichenoid plaques, skin thickening, movable scle-
osis; 3  thickened skin with limited motion, but
inchable; 4  hidebound skin, unmovable, unpinch-
ble) was performed and documented on a designed
orm as percentage of BSA involved equaling 100%
or each region (Figure 2). Thus, for each region the
igure 1. Deﬁnition of body surface areas by dividing the patient’s
ody surface into 10 regions (1  head, neck, and scalp; 2  chest;
 abdomen and genitals; 4  back and buttocks; 5  right arm;
 right hand; 7  left arm; 8  left hand; 9  right leg and foot;cnd 10  left leg and foot).oding from 0 to 4 is considered to be mutually ex-
lusive so that the total is always 100% of each region.
ypo- or hyperpigmentation of skin was included as
core 1 for proper documentation of color changes
nd distinction from normal skin, although these
anifestations describe inactive cGVHD lesions. Be-
ause a confounding erythematous rash in cGVHD
esions can respond differently to therapy, it was doc-
mented in addition in score 3 and score 4 but not
core 2 areas. The later coding describes mechanical
haracteristics of affected skin. For reasons of simplic-
ty and in view of color changes in small percentages
f BSA confoundig erythematous rash was docu-
ented as 0%, 25%, 50%, 75%, or 100% of BSA of
ach region.
tudy Design and Training of Assessors
Four physicians (1 with 15 years, 2 with 5 to 10
ears, and 1 with 6 months of clinical experience in
ematopoietic stem cell transplantation [HSCT]) with
o prior exposure to this skin-scoring instrument par-
icipated as assessors in the 2-day study session. In the
orning of the ﬁrst day all assessors were given a skin
xamination training lecture by an expert dermatolo-
ist explaining the division of the BSA into 10 regions,
he calculation of affected BSA by each region, and the
iversity of cutaneous manifestations of cGVHD.
owerpoint slides with cartoons of the scoring system
nd photographs of chronic cutaneous GVHD were
iscussed. Thereby, codes 0 to 4 were explained in
etail according to the photographs presented. Train-
es were encouraged to challenge the expert derma-
ologist’s assessment resulting in consensus on the
oding presented for every single photograph. Then,
kin palpation and description of cutaneous manifes-
ations was demonstrated on 2 volunteers with normal
kin and 2 patients with cGVHD. Color changes,
arious degrees of skin thickening, and skin motion
ere discussed, and trainees performed skin palpation
hemselves in the presence of the expert dermatolo-
ist. The practical part of the training session focused
n reaching a consensus on the coding of the cutane-
us manifestations.
At the end of the 2-hour training session all ob-
ervers felt comfortable with the New Chronic
VHD Skin Score. They received a short version of
he coding and the cartoon with the 10 body regions
nd were asked to assess the skin by palpation and
linical observation and ﬁll in their ﬁndings in the
rovided scoring forms. They were not allowed to
eview patients’ medical history or compare results.
atients and assessors were coded and scoring forms
ere collected after each examination by the study
oordinator.
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H. T. Greinix et al.718All 16 patients were examined separately in differ-
nt rooms by the 4 assessors to analyze the amount of
isagreement between them (interobserver reliability).
o determine intraobserver reliability, all assessors
xamined every patient on 3 separate occasions within
1-day period, but with at least 7 other examinations
Figure 2. Documentation sheet fn between. For logistical reasons, 4 patients with SSc 2ad to be included, and all assessments were per-
ormed within a 2-day period.
tatistical Analysis
For the intraclass correlation coefﬁcient (ICC) the
Skin Score of Chronic GVHD.-way random effects model was used where both
p
s
a
I
t
r
S
s
b
t
w
s
t
p
[
I
w
v
n
s
s
o
a
t
ﬁ
l
I
a
p
e
w
t

d
l
u
d
r
w
t
r
r
c
l
R
t
G
c
s
t
i
t
o
w
b
r
s
c
i
2
w
i
s
e
I
i
R
N
r
p
o
n
i
c
i
l
a
e
e
c
T
C
0
1
2
3
4
E
E
T
Skin Score Validation—Chronic Graft-versus-Host Disease 719atients and assessors were interpreted as a random
election of a larger population according to Shrout
nd Fleiss [13] and McGraw and Wong [14]. This
CC model calculates the random effect of the pa-
ients, the random effect of the assessors, and the
esidual effect in a 2-way randomized block design.
hrout and Fleiss called it ICC type 2. In the SPSS
tatistical software the type 2 model can be speciﬁed
y the option “Absolute Agreement” or “Consis-
ency.” The assessors should agree in absolute terms
hen measuring an affected area. That means that the
ystematic variability of assessors is relevant. Hence,
he “Absolute Agreement” is the type of ICC em-
loyed in this article. In their article, Shrout and Fleiss
13] designated this intraclass reliability coefﬁcient as
CC(2,1).
The corresponding formula is deﬁned by
ICC (bv ev) ⁄ ((bv) ((k 1) ev)
 ((k (rv ev)) ⁄ n))
here bv is the between patient variance, rv is the
ariance for raters, ev is the error variance, and k is the
umber of raters.
SPSS displays 2 ICCs, 1 concerning single mea-
ures and 1 concerning average measures. In this manu-
cript the interobserver agreement is investigated to ﬁnd
ut whether we can assume that the judgment of 1
ssessor is the same as that of the others. Therefore,
he “single measures” ICC was the appropriate coef-
cient used in our analysis. For the intraobserver re-
iability the ICC was used in an analogous way. An
CC close to 0 means a high intraobserver variability,
n ICC of 1 stands for excellent agreement. For the
urpose of this study, correlations 0.9 were consid-
red excellent, correlations ranging from 0.6 to 0.9
ere considered good, correlations ranging from 0.4
o 0.6 were considered moderate, and correlations
0.4 were considered low agreement.
The coefﬁcient of variation was calculated in ad-
ition. It allows comparison of the variation of popu-
ations that have signiﬁcantly different mean values
sing the mean as unit. For calculations of the pooled
ata of all 10 body regions the different size of these
egions should be taken into account. Hence, we
eighted the region percent of every score within 1 of
he 10 partition regions by the percent of the partition
egion of the total BSA. In this way the 10 partition
egions were comparable to each other.
SPSS statistical software system (SPSS Inc., Chi-
ago, IL, versions 12.0 and 13.0) was used for calcu-
ations.
ESULTS
According to Shulman and colleague’s classiﬁca-
ion [7] all enrolled patients had extensive chronic *VHD with 2 organs involved. In 11 of 12 patients
GVHD was histologically conﬁrmed consisting of
clerodermatous type in 9 and lichenoid type in 3 at
he time of onset. At study entry 8 of 16 patients
ncluding 6 of 12 with cGVHD presented with ery-
hema in body regions with skin involvement scores 3
r 4. An average of 3.5 (range, 2-10) body regions
ere affected by erythema in these patients involving
etween 25% and 75% of surface area of the various
egion.
Applying the recently published new NIH Con-
ensus score for chronic GVHD [8] to our patient
ohort at study entry all 12 had cutaneous cGVHD,
ncluding 6 with a severity score of III, 4 with II, and
with I; 6 patients had eye involvement, including 4
ith a severity score of II, and 2 with I; 4 patients had
nvolvement of oral mucosa including 2 with a severity
core of III, and 2 with I; 2 patients had musculoskel-
tal involvement including 1 with a severity score of
II, and another with II; and 2 patients had liver
nvolvement score I.
eproducibility (Intraobserver Reliability) of the
ew Chronic GVHD Skin Score
Four observers examined every patient on 3 sepa-
ate occasions and scored skin GVHD according to
ercentage BSA affected and its manifestation in each
f 10 regions. The average time to perform 1 exami-
ation was 8 minutes (range, 4-16 minutes).
Table 2 shows the distribution of cutaneous man-
festations of the study population demonstrated by
oefﬁcients of variation calculated for the ﬁrst exam-
nation.
The intraclass correlation coefﬁcient was calcu-
ated for all 4 observers according to manifestations
nd is shown in Table 3. The ICC was good to
xcellent in almost all scores including assessment of
rythema in areas of score 3 and score 4. No signiﬁ-
ant differences between the most experienced ob-
able 2. Cutaneous Manifestations of Study Patients Shown by
oefﬁcients of Variation
Coefficient of Variation
Score
Observer
1
Observer
2
Observer
3
Observer
4
0.856 1.141 1.126 1.430
1.466 1.309 1.379 3.842
2.305 2.088 1.518 1.568
2.272 2.235 1.737 1.977
2.608 2.815 2.561 2.819
rythema 3* 0.461 0.323 0.545 0.260
rythema 4* 0.421 0.267 0.333 0.127
he coefﬁcient of variation for examination 1 was calculated ac-
cording to score and observer. Each of the 10 body regions were
entered into the calculation as percent weighted by the region
portion of the total body surface.Erythema in areas of score 3 and score 4.
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H. T. Greinix et al.720erver (observer 1) and the least experienced one (ob-
erver 4) were noted.
recision (Interobserver Reliability) of the New
hronic GVHD Skin Score
To assess discrepancies in scoring according to
anifestations of cutaneous involvement and percent-
ge of body surface area affected among the 4 physi-
ians, the intraclass correlation coefﬁcient was calcu-
ated as shown in Table 4. ICCs above 0.4 to above 0.6
ndicated moderate to good interrater reliability in score
, score 3, and score 4 lesions, whereas in score 1 and
core 2 lesions signiﬁcantly (.001) less interrater
greement was observed.
In addition, the intraclass correlation coefﬁcient
as calculated for observers 1 to 3 alone to assess the
mpact of clinical experience on interobserver reliabil-
ty. Thereby, in all scores and examinations a marked
mprovement in interobserver reliability was seen as
emonstrated by higher ICCs even in score 1 and
core 2 regions (Table 5).
able 3. Reproducibility (Intraobserver Reliability) According to
anifestations of Cutaneous Involvement and Observers Shown as
ntraclass Correlation Coefﬁcients
Score
Observer
1
Observer
2
Observer
3
Observer
4
0.953 0.932 0.633 0.843
0.784 0.849 0.879 0.307
0.516 0.807 0.804 0.675
0.728 0.674 0.711 0.774
0.877 0.810 0.662 0.863
rythema 3* 0.637 0.732 0.812 0.658
rythema 4* 0.610 0.633 0.491 0.883
he intraclass correlation coefﬁcient was calculated for every ob-
server according to score of cutaneous chronic graft-versus-host
disease assessment during 3 examinations of all patients. Each of
the 10 body regions was entered into the calculation as percent
weighted by the area portion of the total body surface.
Erythema in areas of score 3 and score 4.
able 4. Precision (Interobserver Reliability) According to
anifestations of Cutaneous Involvement and Examination Performed
y All Assessors Shown as Intraclass Correlation Coefﬁcients
Score Examination 1 Examination 2 Examination 3
0.648 0.690 0.373
0.347 0.355 0.731
0.234 0.264 0.313
0.493 0.603 0.192
0.692 0.507 0.544
rythema 3* 0.378 0.358 0.593
rythema 4* 0.391 0.373 0.414
he intraclass correlation coefﬁcient was calculated according to
score of cutaneous chronic graft-versus-host disease and exam-
ination of all patients by the four observers. Each of the 10 body
regions was entered into the calculation as percent weighted by
the area portion of the total body surface.tErythema in areas of score 3 and score 4.Of note, the interrater agreement was improved in
he third examination compared to the ﬁrst 1 in score 1
nd score 2 lesions and in erythematous areas of score
and score 4 cutaneous manifestations (Tables 4 and 5).
ISCUSSION
In cutaneous cGVHD percentage of BSA affected
nd depth of sclerotic involvement are key determi-
ants for administration of immunosuppressive ther-
py, its duration and intensity, treatment response,
nd impairment of patients’ quality of life [1,15].
mong other factors, and as demonstrated in previous
tudies, a higher percentage of skin involvement at
ime of diagnosis of cGVHD correlated with an in-
reased risk of transplant-related mortality (TRM)
9,16]. Sclerotic skin manifestations may be variable
17] and so far, have been difﬁcult to measure reli-
bly. In view of the lack of a validated skin score for
ssessing sclerotic skin changes in cGVHD we de-
igned a New Chronic GVHD Skin Score approxi-
ately 10 years ago to distinguish between normal skin
grade 0), discoloration (grade 1), lichenoid plaques and
ovable sclerosis (grade 2), thickened skin with limited
otion (grade 3), and hidebound unmovable skin (grade
) for use by trained blinded assessors in a recently
ompleted randomized trial in cGVHD patients [12].
owever, this New Chronic GVHD Skin Score has
ot been validated yet.
This validation study demonstrates the good to
xcellent reproducibility of the skin assessment by
oth young and experienced transplant physicians in
ll cutaneous manifestations including erythema in
reas of score 3 and score 4. In addition, moderate to
ood interrater agreement was observed for score 0
normal skin), score 3 (thickened skin with limited
otion), and score 4 lesions (hidebound unmovable
kin) between experienced as well as less experienced
able 5. Precision (Interobserver Reliability) According to
anifestations of Cutaneous Involvement and Examination Performed
y Experienced Assessors Shown as Intraclass Correlation Coefﬁcient
Score Examination 1 Examination 2 Examination 3
0.676 0.729 0.495
0.426 0.512 0.790
0.332 0.284 0.494
0.607 0.631 0.308
0.763 0.583 0.554
rythema 3* 0.477 0.394 0.689
rythema 4* 0.483 0.495 0.503
he intraclass correlation coefﬁcient was calculated according to
score of cutaneous chronic graft-versus-host disease and exam-
ination of all patients by observers 1 to 3. Each of the 10 body
regions was entered into the calculation as percent weighted by
the area portion of the total body surface.
Erythema in areas of score 3 and score 4.ransplant physicians. Of note, a marked improvement
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Skin Score Validation—Chronic Graft-versus-Host Disease 721n interobserver reliability of all scores and examina-
ions was observed when only assessments of the 3
xperienced physicians were compared. Especially in
core 1 and score 2 lesions and in erythematous areas
f score 3 and score 4 the interrater agreement was
mproved in the third examination compared to the
rst one, indicating the importance of training when
sing a new and elaborate skin assessment tool. Con-
equently, this New Chronic GVHD Skin Score could
hus be used for the documentation of cutaneous in-
olvement in clinical trials investigating immunosup-
ressive therapies. With appropriate training by a spe-
ialist its use is very feasible and can be performed
ithin a very short time so as not to interfere with
ther critical clinical activities of the examiners.
Recently, the NIH Consensus Group on Chronic
VHD [18] recommended for skin scoring a distinc-
ion into erythematous changes, movable sclerosis,
onmovable/subcutaneous sclerosis or fasciitis, and
lceration. The later is to be assessed by measuring
he largest diameter of the largest ulcer, whereas the
ormer 3 manifestations are each to be assessed sepa-
ately according to the percent of BSA involved.
hronic cutaneous GVHD is to be documented ac-
ording to 8 body regions consisting of head/neck/
calp, anterior torso, posterior torso, left upper ex-
remity, right upper extremity, left lower extremity
ncluding left buttock, right lower extremity including
ight buttock, and genitalia. In our New Chronic
VHD Skin Score patients‘ BSA is divided into 10
egions. Although, the deﬁnition of body regions dif-
ers between the NIH Consensus Group recommen-
ations and our skin score, the documentation of per-
entages of affected BSA for each separate region
llows a comparison of both scoring tools with regard
o extent of cutaneous involvement by cGVHD at the
ime of the individual assessment.
In close cooperation with our dermatologists spe-
ialized in assessing GVHD, skin manifestations were
ifferentiated into 5 categories including normal skin
score 0) and changes in pigmentation (score 1). The
ater were incorporated to allow documentation of
00% of BSA for each of 10 anatomic regions. Even
hough changes in pigmentation do not necessarily
ndicate activity in cGVHD per se but occur gradually
nd are perceptible only across long time intervals,
hey can still be recorded in the assessment forms.
hen the New Chronic GVHD Skin Score was de-
eloped approximately 10 years ago the term “lichen-
id” was in clinical use, was frequently conﬁrmed by
ppropriate skin biopsies and thus, was included as
core 2 in our skin assessment tool. Considering the
ower interobserver agreement on this skin manifes-
ation in our study, however, this term most likely is
ess well deﬁned compared with other scores. Because
nterobserver reliability on score 2 improved from the
rst to the third examination and was better among ahe more experienced physicians, more training could
urther improve results.
The term “erythematous rash” is used in the NIH
onsensus Group recommendations for a variety of
uperﬁcial skin eruptions of cGVHD including papu-
ar, poikiloderma, lichen planus-like, papulosqua-
ous, and keratosis pilaris-like rashes [18]. Thus, our
core 1 describing discolored skin, hypo- or hyper-
igmentation, or alopecia would ﬁt into the NIH
erm “erythematous rash,” as would score 2 describ-
ng lichenoid plaques. When the New Chronic
VHD Skin Score was developed approximately 10
ears ago, additional documentation of erythema for
cores 3 and 4 lesions was included, whereby the term
erythema” meant exclusively maculopapular rash or
edness, and thus, active GVHD. Erythema was doc-
mented in our New Chronic GVHD Skin Score as
%, 25%, 50%, 75%, or 100% of BSA of each region.
his offers the possibility to distinguish measure-
ents of therapeutic response both according to skin
hickness and rash. Because underlying sclerosis is
nown to resolve slowly, if ever, and erythema in these
reas can respond to immunosuppressive therapies
aster, our New Chronic GVHD Skin Score could be
sed for precise monitoring of responses of various
utaneous manifestations of cGVHD as a function of
ime. However, its sensitivity to change will have to be
valuated in future studies. Whether documentation
f separate entities, for example, score 1 and score 2
nd erythema in score 3 and score 4 as used in our skin
ssessment tool or global documentation of a variety
f superﬁcial skin changes under the term “erythem-
tous rash” as used by the NIH Consensus Group, is
ore meaningful will have to be investigated in fur-
her studies including response evaluation over time.
Up to the present, no validated scoring system for
clerotic skin changes of cGVHD exists. The original
odnan total skin thickness score for progressive sys-
emic sclerosis assessed cutaneous thickening in 26
ody areas utilizing a rating of 0 (normal thickness) to
(extreme thickening) [10]. This scale included areas
elt to be difﬁcult to assess reliably (toes), areas that
re normally relatively thickened (upper back), and
verrepresented anatomic areas of relatively small
SA (right and left breast individually as opposed to
hest and abdomen). Accordingly, a modiﬁed Rodnan
m-Rodnan) total skin thickness score has been in
idespread use in which 17 anatomic areas are scored
y clinical palpation using a 0 to 3 scale (0 is normal
nd 1 to 3 reﬂect mild, moderate, and severe skin
hickening) [19]. However, this score does not mea-
ure lichen sclerosus-like changes, subcutaneous in-
olvement without overlying skin thickening, or
ascial involvement, whereas the Vienna Skin Score
resented here distinguishes between superﬁcial
movable) and deep (hidebound) sclerosis involving
wide area of skin, ﬁbrosis of subcutaneous fat
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H. T. Greinix et al.722eptae, and fasciitis. In a similar manner, the NIH
onsensus Group recommendations distinguish be-
ween “dermal” (movable) and “deep” (nonmovable/
ubcutaneous) sclerosis [18].
Measurements of skin thickness are suitable for
uantiﬁcation of sclerotic processes, and are necessary
or an exact evaluation of the course of the disease.
uch measurements can be performed histologically
17]. However, biopsies are invasive, and sequential
istologic examinations are not well tolerated, as
brotic skin when present does not heal easily. So far,
ew reports on use of imaging methods in patients
ith sclerotic skin manifestations of cGVHD have
een published [20,21]. Our New Chronic GVHD
kin Score provides a noninvasive, accurate, and fea-
ible tool for use in selected clinical trials. However,
e are aware of the limitations of our work including
he small number of cGVHD patients and observers
articipating in this single-center study. Thus, conﬁr-
ation of our ﬁndings in larger and diverse patient
ohorts with cGVHD in a multicenter trial design are
ighly warranted.
Our skin assessment tool was originally developed
o document objectively cutaneous manifestations of
GVHD for a clinical trial seeking regulatory ap-
roval. Our assessors can be considered to be blinded
ecause they had no information on patient history or
mmunosuppressive medication. In view of the good
o excellent intraobserver reliability for almost all
cores observed in this validation study the use of this
kin assessment tool by an appropriately trained ob-
erver could be recommended. Our results support
he use of the same trained observer during a clinical
rial because intrarater agreement was higher than the
nterrater one. Whether interobserver reliability can
e improved by intensifying training and/or using
ore experienced transplant physicians as observers,
as to be investigated in further validation studies with
arger patient cohorts. Considering the good to excellent
eproducibility of all scores by all observers our New
hronic GVHD Skin Score should be further investi-
ated using scores 0 to 4 to allow documentation of
00% of the BSA. For use in clinical trials assessments
an be supported by photography. Because the NIH
onsensus Group recommendations provide excellent
eﬁnitions on measuring therapeutic response with re-
ards to organ-speciﬁc assessments, objective measures
f GVHD activity, and global ratings [18] and consid-
ring the historic development, our skin assessment tool
eant to precisely document cutaneous GVHD could
e incorporated into further research activities of the
IH Consensus Group. Translating our individual
ssessments into arithmetical numbers for deﬁning
otal skin scores would be possible using our scoring
ool. However, further studies comparing total skin
cores with clinical ﬁndings and severity of cGVHD
ould have to be performed for assessing whether thisew skin scoring tool can demonstrate clinical beneﬁt.
t should be noted that the NIH Consensus Group
ecently recommended to select primary and second-
ry study endpoints according to their ability to dem-
nstrate clinical beneﬁt [22].
In conclusion, our New Chronic GVHD Skin
core for assessment of cutaneous cGVHD patients, is
promising reproducible, accurate, and feasible tool
or use in clinical trials. Based on our results we would
ike to encourage investigators to employ our New
hronic GVHD Skin Score in further studies with
GVHD patients.
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